About this trial

RATIONALE: To improve strategies for detection and prevention of early-stage disease.

PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.

Eligibility criteria

Qualifiers

Has at least one first-degree relative (mother, sister, or daughter) with ovarian, primary peritoneal, or fallopian tube cancer

Has at least two first or second degree relatives diagnosed before age 50 with either ovarian, primary peritoneal, fallopian tube, and/or pancreatic cancer who have tested positive for hereditary cancer syndrome that includes an increased risk of gynecologic cancer (e.g., BRCA1/2 or Lynch Syndrome)or have increased risk as deemed by a certified genetic counselor

A personal or family history of a hereditary cancer syndrome that includes an increased risk of gynecologic cancer

Increased risk as deemed by a certified genetic counselor

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Ca-125
  • screening questionnaire administration
  • Surgery

Treatment groups

6,000 Participants
are divided into 3 treatment groups

Locations

1
Robert H. Lurie Comprehensive Cancer Center at Northwestern University60611-3013, ChicagoIllinois, United States

Sponsors and collaborators

Northwestern University

Lead sponsor

National Cancer Institute (NCI)

Collaborator